53
Big Data in Biomedicine: Transla3ng 300 trillion points of data into new drugs and diagnos3cs Atul Bu;e, MD, PhD Chief, Division of Systems Medicine, Departments of Pediatrics, Gene3cs, and, by courtesy, Computer Science, Pathology, and Medicine Center for Pediatric Bioinforma3cs, LPCH Stanford University abu;[email protected] @atulbu;e @ImmPortDB

2014 07 ismb personalized medicine

Embed Size (px)

DESCRIPTION

Atul Butte presentation at ISMB 2014

Citation preview

Page 1: 2014 07 ismb personalized medicine

Big  Data  in  Biomedicine:  Transla3ng  300  trillion  points  of  data  into  new  drugs  and  diagnos3cs      

Atul  Bu;e,  MD,  PhD  Chief,  Division  of  Systems  Medicine,    

Departments  of  Pediatrics,  Gene3cs,    and,  by  courtesy,  Computer  Science,  Pathology,  and  Medicine  

Center  for  Pediatric  Bioinforma3cs,  LPCH  Stanford  University  

abu;[email protected]    @atulbu;e  

@ImmPortDB  

Page 2: 2014 07 ismb personalized medicine

Disclosures  •  Scien'fic  founder  and    

advisory  board  membership  –  Genstruct  –  NuMedii  –  Personalis  –  Carmenta  

•  Honoraria  for  talks  –  Lilly  –  Pfizer  –  Siemens  –  Bristol  Myers  Squibb  –  AstraZeneca  –  Roche  –  Genentech  

•  Past  or  present  consultancy  –  Lilly  –  Johnson  and  Johnson  –  Roche  –  NuMedii  –  Genstruct  –  Tercica  –  Ecoeos  –  Ansh  Labs  –  Prevendia  –  Samsung  

–  Assay  Depot  –  Regeneron  –  Verinata  –  Geisinger  –  Covance  

•  Corporate  Rela'onships  –  Northrop  Grumman  –  Aptalis  –  Thomson  Reuters  

•  Speakers’  bureau  –  None  

•  Companies  started  by  students  –  Carmenta  –  Serendipity  –  NuMedii  –  S'mulomics  –  NunaHealth  –  Praedicat  –  MyTime  –  Flipora    

Page 3: 2014 07 ismb personalized medicine

Big  Data  in    Biomedicine  

Page 4: 2014 07 ismb personalized medicine
Page 5: 2014 07 ismb personalized medicine

Nearly  1.4  million  microarrays  available  Doubles  every  2-­‐3  years  

Bu;e  AJ.  Transla3onal  Bioinforma3cs:    coming  of  age.  JAMIA,  2008.  

Page 6: 2014 07 ismb personalized medicine
Page 7: 2014 07 ismb personalized medicine
Page 8: 2014 07 ismb personalized medicine

127  million  substances  x  740,000  assays    1.2  billion  points  of  data  within  a  grid  of    100  trillion  cells    ~250  million  ac3ve  substances  

Page 9: 2014 07 ismb personalized medicine

5,178  compounds  ·∙                1,300  off-­‐patent  FDA-­‐approved  drugs  ·∙                700  bioac've  tool  compounds  ·∙                2,000+  screening  hits  (MLPCN  and  others)  3,712  genes  (shRNA  +  cDNA)  ·∙                targets/pathways  of  FDA-­‐approved  drugs  (n=900)  ·∙                candidate  disease  genes  (n=600)  ·∙                community  nomina'ons  (n=500+)  15  cell  types  ·∙                Banked  primary  cell  types  ·∙                Cancer  cell  lines  ·∙                Primary  hTERT  immortalized  ·∙                Pa'ent  derived  iPS  cells  ·∙                5  community  nominated  

Page 10: 2014 07 ismb personalized medicine
Page 11: 2014 07 ismb personalized medicine

Protein

Page 12: 2014 07 ismb personalized medicine

Protein

Cancer  markers  

Transplant  Rejec3on  markers  

Page 13: 2014 07 ismb personalized medicine

Preeclampsia:  large  cause  of  maternal  and  fetal  death  

•  Incidence  •  5-­‐8%  of  all  pregnancies  in  the  U.S.  and  worldwide  

•  4.1  million  births  in  the  U.S.  in  2009  

•  Up  to  300K  cases  of  preeclampsia  annually  in  the  U.S.  

• Mortality  •  Responsible  for  18%  of  all  maternal  deaths  in  the  U.S.  

•  Maternal  death  in  56  out  of  every  100,000  live  births  in  US  

•  Neonatal  death  in  71  out  of  every  100,000  live  births  in  US  

•  Cost  •  $20  billion  in  direct  costs  in  the  U.S  annually  

•  Average  hospital  stay  of  3.5  days  Linda  Liu  

Ma;  Cooper  Bruce  Ling  

Page 14: 2014 07 ismb personalized medicine
Page 15: 2014 07 ismb personalized medicine

New  markers  for  preeclampsia  

p  value   3.49  X  10-­‐4  1.79  X  10-­‐5  

ng/m

l  

p  value  =  1.92  X  10-­‐8  

Control  N=16  

Preeclampsia  N=15  

Control  N=16  

Preeclampsia  N=17  

GA  23-­‐34  weeks   GA  >  34  weeks  

ng/m

l  

Gesta3onal  age  (weeks)  

march of dimes®

prematurity research center

VERSION: MOD_PRC_LOGO_R7G_082712

at STANFORD University School of Medicine

Linda  Liu  Bruce  Ling  

Page 16: 2014 07 ismb personalized medicine
Page 17: 2014 07 ismb personalized medicine

Sequencing  Excitement  •  454/Roche,  Life  Technologies  •  Helicos:  $30k  genome  •  Pacific  Biosystems:  sequence  human  genome  in  15  minutes  

•  Run  'mes  in  minutes    at  a  cost  of  hundreds  of  dollars  

•  Complete  Genomics:  80  genomes/day  

•  Ion  Torrent    and  Illumina:  ~$1500  per    genome  

•  Oxford:  USB  s'ck  

Page 18: 2014 07 ismb personalized medicine

Lancet,  375:1525,  May  1,  2010.    

Page 19: 2014 07 ismb personalized medicine

Credit:  Euan  Ashley,  Russ  Altman,  Steve  Quake,  Lancet  

Page 20: 2014 07 ismb personalized medicine

•  Study  published  in  2008  in  Inflammatory  Bowel  Disease  

•  Crohn’s  Disease  and  Ulcera've  Coli's  

•  Inves'gated  9  loci  in  700  Finnish  IBD  pa'ents  

•  We  record  100+  items  –  GWAS,  non-­‐GWAS  papers  –  Disease,  Phenotype  –  Popula'on,  Gender  –  Alleles  and  Genotypes  –  p-­‐value  (and  confidence)  –  Odds  ra'o  (and  confidence)  –  Technology,  Study  design  –  Gene'c  model  

•  Mapped  to  UMLS  concepts  Rong  Chen  Optra  Systems  

Page 21: 2014 07 ismb personalized medicine

•  Study  published  in  2008  in  Inflammatory  Bowel  Disease  

•  Crohn’s  Disease  and  Ulcera've  Coli's  

•  Inves'gated  9  loci  in  700  Finnish  IBD  pa'ents  

•  We  record  100+  items  –  GWAS,  non-­‐GWAS  papers  –  Disease,  Phenotype  –  Popula'on,  Gender  –  Alleles  and  Genotypes  –  p-­‐value  (and  confidence)  –  Odds  ra'o  (and  confidence)  –  Technology,  Study  design  –  Gene'c  model  

•  Mapped  to  UMLS  concepts  

Page 22: 2014 07 ismb personalized medicine

•  Study  published  in  2009  in  Rheumatology  

•  Ankylosing  spondyli's  

•  Inves'gated  8  SNPs  in  IL23R  in  2000  UK  case-­‐control  pa'ents  

•  Tables  can  be  rotated  •  NLP  is  hard  

Page 23: 2014 07 ismb personalized medicine

•  Study  published  in  2009  in  Rheumatology  

•  Ankylosing  spondyli's  

•  Inves'gated  8  SNPs  in  IL23R  in  2000  UK  case-­‐control  pa'ents  

•  Tables  can  be  rotated  •  NLP  is  hard  

Page 24: 2014 07 ismb personalized medicine

•  Study  published  in  2009  in  Rheumatology  

•  Ankylosing  spondyli's  

•  Inves'gated  8  SNPs  in  IL23R  in  2000  UK  case-­‐control  pa'ents  

•  Tables  can  be  rotated  •  NLP  is  hard  

Page 25: 2014 07 ismb personalized medicine
Page 26: 2014 07 ismb personalized medicine

What  are  the  alleles  for  rs1004819?  

Page 27: 2014 07 ismb personalized medicine

Alleles  for  rs1004819  are  C  and  T  

~11%  of  records  reported  genotypes  in  the  nega3ve  strand  

Page 28: 2014 07 ismb personalized medicine
Page 29: 2014 07 ismb personalized medicine
Page 30: 2014 07 ismb personalized medicine
Page 31: 2014 07 ismb personalized medicine

Number  of  papers  curated  

Number  of  records  

Dis3nct  SNPs   Diseases  and  phenotypes  

~19,000   ~1.6  million   ~473,000   ~7,400  

Rong  Chen  Anil  Patwardhan  

Michael  Clark  Optra  Systems  

Personalis  

VARIMED:  Variants  Informing  Medicine  

Chen  R,  Davydov  EV,  Sirota  M,  Bu;e  AJ.    PLoS  One.    2010  October:  5(10):  e13574.  

Page 32: 2014 07 ismb personalized medicine
Page 33: 2014 07 ismb personalized medicine

Diseases  and  Traits  • Risk  factors  are  associated  with  an  increased  likelihood  of  developing  a  given  diseases  •  Smoking  à  chronic  obstruc've  pulmonary  disease  

• Risk  factors  are  iden'fied  for  diseases  through  large  scale  epidemiological  studies,  which  are  resource  intensive  • GWAS  have  iden'fied  gene'c  variants  for  thousands  of  diseases  and  traits  •  If  traits  and  diseases  share  the  same  associated  gene'c  variants,  could  the  trait  be  used  to  suggest  risk  factors  for  disease?  

Li  L,  Ruau  DJ,  Patel  CJ,  Weber  SC,  Chen  R,  Tatonej  NP,  Dudley  JT,  Bu;e  AJ.    Science  Transla3onal  Medicine,  2014,  6(234).  

Li  Li  

Page 34: 2014 07 ismb personalized medicine

EMR Cohort

Identify significant disease-trait genetic associations and clinically validate using EMR data

Gene counts > 3

Disease (n=201)

Varimed  

TF-IDF weighing Cosine distance Random shuffling

Trait (n=85)

Disease (n=69)

Trait (n=249)

Disease-Trait Pair (n=120)

p < 1e-8 Disease modules (n=8)

Gene3cs  Module  

D

Clinical  Valida3on  

Novel predictions (n=26)

T

q ≤ 0.01

D

Published findings (n=94)

T D

D

D D

T D

T T

T T

Trait modules (n=7)

Complications

Diagnostic tests

Risk factors

1st dx

After dx Before dx

1st dx

Li  Li  

Page 35: 2014 07 ismb personalized medicine

Assessing  significance  of  disease-­‐trait  (D-­‐T)  pair  

•  Each  gene  within  individual  disease  or  trait  by  taking  into  account  the  frequency  of  the  gene:  Term  Frequency–Inverse  Document  Frequency  •  2-­‐idf(i,  j)  =  2(i,  j)  ×  idfi,  =  ni,  j/(∑k  nk,  j)  x  log(D/Di)  which  adjusted  the  score  of  6(i,  j)  by  taking  into  account  the  popularity  level  of  the  gene  i.    

•  e.g,  154  D+T,  28  genes  in  Alzheimer's  disease  and  5  genes  in  ESR,  CR1  was  in  common  •  s-­‐idf  (AD)=1/28  x  log(154/2,10)=0.067  •  s-­‐idf  (ESR)=1/5  x  log(154/2,10)=0.377  

•  D-­‐T  distance  score  was  calculated  using  Cosine  distance  to  evaluate  similarity  between  all  pairs.  

•  Randomly  sampling  all  the  genes  across  all  the  traits,  and  calculated  the  D-­‐T  similarity,  repeated  1,000  'mes  and  generated  the  q  value  based  on  the  number  of  the  samplings.  

∑∑∑

==

=

×

×=

•=−

n

i in

i i

n

i ii

TD

TDTDTDTDsimilarityine

12

12

1

)()(),(cos =  0.9274524  

Li  L,  Ruau  DJ,  Patel  CJ,  Weber  SC,  Chen  R,  Tatonej  NP,  Dudley  JT,  Bu;e  AJ.    Science  Transla>onal  Medicine,  2014,  6(234).  

Li  Li  

Page 36: 2014 07 ismb personalized medicine

Li  Li  

Page 37: 2014 07 ismb personalized medicine

Li  Li  

Page 38: 2014 07 ismb personalized medicine

Categoriza3ons  for  known  D-­‐T  pairs  and  discover  poten3al  confounders  in  GWAS  studies  

38 pairs 27 pairs 28 pairs

93 pairs

T D

Gene3c  Variants  

T D

Gene3c  Variants  

Timing  of  Disease  Progression  

Risk  Factor   Consequence  

T

D

Gene3c  Variants  

Diagnos3c  Test  

Li  Li  

Page 39: 2014 07 ismb personalized medicine

Diagnos3c  tests  where  traits  occur  at  the  same  3me  as  disease  onset  

An3body  3ter  

Hepa<<s  B  vaccine  response  Png  et  al,  Hum  Mol  Genet,  2011  

Even  though  this  GWAS  did  not  explicitly  par'cipants  with  the  autoimmune  diseases  above,  our  approach  inferred  known  rela'onships  between  diseases  and  traits  based  on  their  shared  gene'c  architecture    

T

D

Gene3c  Variants  

Diagnos3c  Test  

Li  Li  

Page 40: 2014 07 ismb personalized medicine

Significant  genes  shared  between  an3body  3ter  and    16  autoimmune  diseases  

Disease   Common  Genes   Genes  Shared   q-­‐value  Alopecia  areata   4   BTNL2;  C6orf10;  RDBP;  TNXB   <0.001  

Ankylosing  spondyli's   2   BTNL2;  LOC100507436   0.001  Asthma   4   BTNL2;  C6orf10;  HLA-­‐DPA1;  NOTCH4;   <0.001  

Biliary  liver  cirrhosis   3   BTNL2;  C6orf10;  HLA-­‐DPB1   0.003  Chronic  hepa''s  b   2   HLA-­‐DPA1;  HLA-­‐DPB1   <0.001  

HIV  infec'on   7   C6orf10;  HLA-­‐C;  LOC100507436;  NOTCH4;  PRRC2A;  RDBP;  TNXB   <0.001  

Membranous  nephropathy   15   AGPAT1;  BAG6;  BTNL2;  C6orf10;  EHMT2;  GPANK1;  LY6G5B;  LY6G6C;  NOTCH4;  PRRC2A;  RDBP;  RNF5;  SLC44A4;  TNXB;  ZBTB12   <0.001  

Mul'ple  sclerosis   7   AGPAT1;  BAG6;  BTNL2;  C6orf10;  EHMT2;  NOTCH4;  TNXB   <0.001  Neonatal  lupus   3   BAG6;  C6orf10;  ZBTB12   <0.001  

Primary  biliary  cirrhosis   3   BTNL2;  C6orf10;  HLA-­‐DPB1   0.005  

Rheumatoid  arthri's   20  AGPAT1;  BAG6;  BTNL2;  C6orf10;  EHMT2;  GPANK1;  HLA-­‐C;  HLA-­‐DPA1;  HLA-­‐DPB1;  

LOC100507436;  LY6G5B;  LY6G6C;  LY6G6F;  NOTCH4;  PRRC2A;  RDBP;  RNF5;  SLC44A4;  TNXB;  ZBTB12  

<0.001  

Systemic  lupus  erythematosus   9   BAG6;  BTNL2;  C6orf10;  GPANK1;  HLA-­‐DPB1;  NOTCH4;  PRRC2A;  TNXB;  ZBTB12   <0.001  

Systemic  sclerosis   3   HLA-­‐DPA1;  HLA-­‐DPB1;  NOTCH4   <0.001  Type  1  diabetes   5   BAG6;  BTNL2;  C6orf10;  HLA-­‐C;  HLA-­‐DPB1   0.001  

Vi'ligo   6   AGPAT1;  BTNL2;  NOTCH4;  RNF5;  SLC44A4;  TNXB   <0.001  Wegener's  granulomatosis   2   HLA-­‐DPA1;  HLA-­‐DPB1   <0.001  

Li  Li  

Page 41: 2014 07 ismb personalized medicine

Risk  factors  where  traits  occur  prior  to  the  disease  onset  and  may  accompany  disease  

Trait   Disease   Common  Genes   Genes  Shared   q-­‐value  

Smoking   Chronic  obstruc've  pulmonary  disease   3   AGPHD1;  CHRNA3;  RAB4B   <0.001  

Gene3cs  Variants  

Known  clinical  study:  Smoking  is  the  primary  risk  factor  for  COPD  although  lixle  was  known  the  pathogenesis  between  smoking  and  COPD.  Pauwels  et  al,  2001,  Vestbo  et  al  2012    In  GWAS  study:  Six  GWAS  studies  are  related  to  COPD  in  VARIMED  and  their  COPD  cohorts  all  are  from  smoking  pa'ents.    Cho  et  al,  2012,  Pillai  SG,  2010,  Wang  et  al  2010,  Cho  et  al,  2010,  lambrechts  et  al,  2010,  Pillai  SG,  2009    As  COPD  occurs  ayer  smoking,  the  variants  associated  with  COPD  could  be  influenced  by  smoking,  and  the  gene'c  variants  for  COPD  could  be  unmasked  if  smoking  confounder  is  excluded  in  GWAS.  

Smoking   COPD  

Li  Li  

Page 42: 2014 07 ismb personalized medicine

Gene3c  Variants  

Consequence  where  traits  occur  aqer  the  disease  onset  Trait   Common  Genes   Genes  Shared   q-­‐value  

Alanine  aminotransferase  levels   1   C12orf51   0.001  

Cholesterol  levels   3   ALDH2;  BRAP;  C12orf51   0.001  

HDL  cholesterol  levels   2   C12orf51;  OAS3   <0.001  

Known  clinical  study:  High  HDL  criterion  was  observed  with  triple  frequency  in  the  ADS  group,  high  cholesterol  diet  was  associated  with  ADS  pa'ents  ,  and    ALT  levels  have  been  seen  to  increase  with  daily  alcohol  intake  in  pa'ents  who  developed  ADS.  Kahl  et  al,  2010;  imhof  et  al,  2001,  Gross  GA,  1994  

 In  GWAS  study:  3  genes  for  cholesterol  levels  reported  by  Kato  et  al.  and  2  genes  for  ALT  and  HDL-­‐C  reported  by  Young  et  al.    could  be  biased  by  alcohol  effect  as  the  authors  did  not  perform  alcohol  intake  adjustment  or  controlled  for  drinking  habits  on  these  genes  in  their  GWAS  studies.  Kato  et  al,  2011;  Kamatani  et  al,  2010    The  GWAS  to  iden'fy  concrete  gene'c  variants  for  these  three  clinical  measurements  should  be  performed  in  pa'ents  without  ADS  as  a  confounder  

Alcohol  dependence  syndrome    (ADS)  

ALT  HDL-­‐C  

ADS  

Li  Li  

Page 43: 2014 07 ismb personalized medicine

27  novel  pairs  Trait   Disease   Common  

Genes   Genes  Shared   q-­‐value  

Mean  corpuscular  volume   Acute  lymphoblas3c  leukemia   1   IKZF1   0.001  Mean  cell  hemoglobin  concentra3on   Alcohol  dependence   1   ALDH2   0.005  

Platelet  count   Alcohol  dependence   1   C12orf51   0.007  Lung  func'on   Alopecia  areata   1   AGER   0.008  

Erythrocyte  sedimenta3on  rate   Alzheimer's  disease   1   CR1   0.004  Prostate-­‐Specific  an'gen  levels   Basal  cell  carcinoma   1   CLPTM1L   0.004  

Eye  color   Chronic  lymphocy'c  leukemia   1   IRF4   0.006  Freckles   Chronic  lymphocy'c  leukemia   1   IRF4   0.008  

Blood  pressure   Esophageal  cancer   3   ALDH2,  C12orf51,  PLCE1   0.009  Factor  vii  coagulant  ac'vity   Esophageal  cancer   1   ADH4   0.008  Serum  magnesium  levels   Gastric  cancer   3   MUC1;  THBS3;  TRIM46   <0.001  

Prostate-­‐Specific  an'gen  levels   Glioma   1   TERT   0.005  Alpha  linolenic  acid  levels   Glucose  intolerance   1   FADS1   0.01  

Alanine  aminotransferase  levels   Hypertension   1   C12orf51   0.003  Serum  transferrin  levels   Hypertension   1   HFE   0.005  

Smoking   Kawasaki  disease   1   RAB4B   0.003  Prostate-­‐Specific  an'gen  levels   Lung  cancer   2   CLPTM1L;  TERT   0.001  

Homocysteine  levels   Melanoma   1   C16orf55   0.01  Protein  c  levels   Melanoma   2   NCOA6;  PIGU   <0.001  

Transferrin  receptor  levels   Metabolic  syndrome   3   APOA5;  BUD13;  ZNF259   <0.001  PR  interval   Open-­‐Angle  glaucoma   1   CAV1   0.002  PR  interval   Restless  legs  syndrome   1   MEIS1   0.003  

Bone  mineral  density   Sudden  cardiac  arrest   1   ESR1   0.006  Acenocoumarol  maintenance  dosage  Systemic  lupus  erythematosus   2   ITGAM;  ITGAX   0.004  

Platelet  count   Tes'cular  cancer   1   BAK1   0.003  Prostate-­‐Specific  an'gen  levels   Tes'cular  cancer   2   CLPTM1L;  TERT   <0.001  Alkaline  phosphatase  levels   Venous  thromboembolism   1   ABO   0.008  

Li  Li  

Page 44: 2014 07 ismb personalized medicine

Independent  pa3ent  cohort  valida3on:  clinical  data  warehouses  

•  STRIDE:  clinical  data  warehouse,  has  ICD9  diagnoses  codes,  CPT  procedure  codes,  and  lab  results  on  over  1.7  million  pediatric  and  adult  pa'ents  at  Stanford  Hospital  and  Clinic,  independent  cohort  1/1/2005  to  7/15/2012  

•  Collabora'ons  also  with  Columbia  University  and  Mount  Sinai  School  of  Medicine  to  validate  findings  

•  Time  frame  for  analysis:  within  one  year  before  the  1st  disease  diagnosis  or  within  one  year  ayer  the  1st  disease  diagnosis  

1st Dx

Target  disease  (case)  Non-­‐target  disease  (control)  

lab lab 1 year 1 year

Li  Li  

Page 45: 2014 07 ismb personalized medicine

Serum  magnesium  levels  and  gastric  cancer  

Li  Li  

Page 46: 2014 07 ismb personalized medicine
Page 47: 2014 07 ismb personalized medicine

immport.niaid.nih.gov  

Page 48: 2014 07 ismb personalized medicine

Digital  compara3ve  effec3veness   Find  precision  subsets  

If  entry  criteria  are  same,  outcome  measures  are  same,  and  comparable  studies,  can  perform  “meta-­‐trial”  

Page 49: 2014 07 ismb personalized medicine
Page 50: 2014 07 ismb personalized medicine

Take  Home  Points  

•  Personalized  medicine    ≥ DNA.    Will  include  other  clinical,  molecular,  and  environment  measures.  

•  We  need  new  inves'gators  who  can  imagine  basic  ques'ons  to  ask  of  these  repositories  of  clinical  and  genomic  measurements.  

•  Bioinforma'cs  is  not  just  about  building  tools.    We  know  our  tools;  we  should  use  them  first.  Don’t  be  afraid  to  test  your  ideas.  

Page 51: 2014 07 ismb personalized medicine

Funded  post-­‐doctoral  posi3ons  in  Transla3onal  Bioinforma3cs  

   Contact  Atul  Bu;e  

abu;[email protected]  

Page 52: 2014 07 ismb personalized medicine

Collaborators  •  Jeff  Wiser,  Patrick  Dunn,  Mike  Atassi  /  Northrop  Grumman  •  Ashley  Xia  and  Quan  Chen  /  NIAID  •  Takashi  Kadowaki,  Momoko  Horikoshi,  Kazuo  Hara,  Hiroshi  Ohtsu  /  U  Tokyo  •  Kyoko  Toda,  Satoru  Yamada,  Junichiro  Irie  /  Kitasato  Univ  and  Hospital  •  Shiro  Maeda  /  RIKEN  •  Alejandro  Sweet-­‐Cordero,  Julien  Sage  /  Pediatric  Oncology  •  Mark  Davis,  C.  Garrison  Fathman  /  Immunology  •  Russ  Altman,  Steve  Quake  /  Bioengineering  •  Euan  Ashley,  Joseph  Wu,  Tom  Quertermous  /  Cardiology  •  Mike  Snyder,  Carlos  Bustamante,  Anne  Brunet  /  Gene'cs  •  Jay  Pasricha  /  Gastroenterology  •  Rob  Tibshirani,  Brad  Efron  /  Sta's'cs  •  Hannah  Valan'ne,  Kiran  Khush/  Cardiology  •  Ken  Weinberg  /  Pediatric  Stem  Cell  Therapeu'cs  •  Mark  Musen,  Nigam  Shah  /  Na'onal  Center  for  Biomedical  Ontology  •  Minnie  Sarwal  /  Nephrology  •  David  Miklos  /  Oncology  

Page 53: 2014 07 ismb personalized medicine

Support  •  Lucile  Packard  Founda'on  for  Children's  Health  •  NIH:  NIAID,  NLM,  NIGMS,  NCI;  NIDDK,  NHGRI,  NIA,  NHLBI,  NCATS  •  March  of  Dimes  •  Hewlex  Packard  •  Howard  Hughes  Medical  Ins'tute  •  California  Ins'tute  for  Regenera've  Medicine  •  Luke  Evnin  and  Deann  Wright  (Scleroderma  Research  Founda'on)  •  Clayville  Research  Fund  •  PhRMA  Founda'on  •  Stanford  Cancer  Center,  Bio-­‐X,  SPARK  

•  Tarangini  Deshpande  •  Alan  Krensky,  Harvey  Cohen  •  Hugh  O’Brodovich  •  Isaac  Kohane  

Admin  and  Tech  Staff  •  Susan  Aptekar  •  Jen  Cory  •  Boris  Oskotsky